Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 04 2022 - 4:05PM
Esperion (NASDAQ: ESPR) today announced that, on August 2, 2022,
the Compensation Committee of Esperion’s Board of Directors granted
13 new employees 66,000 restricted stock units (RSUs) under
Esperion’s 2017 Inducement Equity Incentive Plan.
The 2017 Inducement Equity Incentive Plan is used
exclusively for the grant of equity awards to individuals who were
not previously an employee or non-employee director of Esperion (or
following a bona fide period of non-employment), as an inducement
material to such individual's entering into employment with
Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing
Rules.
Each RSU will vest and become exercisable as to 25
percent of the shares on the one-year anniversary of the
recipient’s vesting commencement date and will vest and become
exercisable as to the remaining 75 percent of the shares in twelve
equal quarterly installments at the end of each quarter following
such anniversary, in each case, subject to each such employee's
continued employment with Esperion on such vesting dates. The RSUs
are subject to the terms and conditions of Esperion’s 2017
Inducement Equity Incentive Plan, and the terms and conditions of
the RSU agreement covering the grant.
Esperion Therapeutics
Esperion works hard to make our medicines easy to
get, easy to take and easy to have. We discover, develop and
commercialize innovative medicines and combinations to lower
cholesterol, especially for patients whose needs aren’t being met
by the status quo. Our entrepreneurial team of industry leaders is
inclusive, passionate and resourceful. We are singularly focused on
managing cholesterol so you can improve your health easily.
Esperion is the leader in the development of convenient oral,
once-daily non-statin LDL-cholesterol lowering drugs for patients
with high levels of bad cholesterol. For more information, please
visit www.esperion.com and follow us on Twitter at
www.twitter.com/EsperionInc.
Contact:Corporate
Communicationscorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024